This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tafreshi, M. J. Articles by Rowles, J. Search for Related Content PubMed PubMed Citation Articles by Tafreshi, M. J. Articles by Rowles, J. Social Bookmarking                         What's this?

A Review of the Investigational Antiarrhythmic Agent Dronedarone

Department of Pharmacy Practice, Midwestern University, Glendale, Arizona

Joie Rowles, PhD

Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern University, Glendale, Arizona, jrowle{at}midwestern.edu

Arrhythmias are a major cause of morbidity and mortality, and atrial fibrillation is the most widespread disorder of cardiac rhythm. Amiodarone is an effective antiarrhythmic agent that has been in clinical use for about 20 years. It is effective for multiple types of arrhythmias, including atrial fibrillation, and has a low incidence of cardiac adverse events, including Torsade de Pointes. It has many noncardiac adverse effects that are serious and limit its long-term use. Dronedarone is an investigational antiarrhythmic agent that is designed to have similar cardiac effects to amiodarone but with fewer adverse effects. This review presents some of the animal and human studies that evaluate the effects of dronedarone.

Key Words: dronedarone • amiodarone • antiarrhythmic • atrial fibrillation • investigational

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 12, No. 1, 15-26 (2007)
DOI: 10.1177/1074248406299069


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?